WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018184267) MRNA-ENCODED NANOBODY AND APPLICATION THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/184267 International Application No.: PCT/CN2017/082096
Publication Date: 11.10.2018 International Filing Date: 27.04.2017
IPC:
C12N 15/13 (2006.01) ,C12N 15/85 (2006.01) ,C12N 15/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
12
Genes encoding animal proteins
13
Immunoglobulins
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Applicants: SOUTHEAST UNIVERSITY[CN/CN]; No.2 Southeast University Road, Jiangning District Nanjing, Jiangsu 211189, CN
Inventors: XIE, Wei; CN
HAO, Rui; CN
ZHOU, Xuechen; CN
ZHOU, Yunyan; CN
SU, Zhipeng; CN
Agent: NANJING SUGAO PATENT AND TRADEMARK FIRM (ORDINARY PARTNERSHIP); Suite 1912 Longtaiguoji Mansion, No.198 Zhongshandonglu Nanjing, Jiangsu 210005, CN
Priority Data:
201710224513.407.04.2017CN
Title (EN) MRNA-ENCODED NANOBODY AND APPLICATION THEREOF
(FR) NANOCORPS CODÉ PAR ARNM ET SON APPLICATION
(ZH) mRNA编码的纳米抗体及其应用
Abstract:
(EN) An mRNA-encoded nanobody and an application thereof, particularly in the field of nanobody drugs. In order to solve the problem mentioned in the specification, a novel concept, method, and system for regulating intracellular proteins by using RNA-encoded nanobodies is employed. A nanobody is encoded by mRNA, and encoding information carried by the mRNA is identified and translated in cells to express a single-chain nanobody that can bind to a target protein. By adopting the method, functions of disease-related proteins inside cells can be effectively and specifically interfered with, thereby achieving the objective of disease treatment. In addition, the method differs from conventional strategies for expressing nanobodies in cells by using DNA or viruses as vectors. The method eliminates the risks associated with changing the genome sequence of host cells, is safe, achieves easy removal, and is highly suitable for clinical drug design and production requirements.
(FR) L'invention concerne un nanocorps codé par ARNm et une application correspondante, en particulier dans le domaine des médicaments à nanocorps. Afin de résoudre le problème mentionné dans la description, un nouveau concept, un procédé et un système de régulation de protéines intracellulaires à l'aide de nanocorps codés par ARN sont utilisés. Un nanocorps est codé par ARNm, et les informations de codage portées par l'ARNm sont identifiées et traduites dans des cellules pour exprimer un nanocorps à chaîne unique qui peut se lier à une protéine cible. Par adoption du procédé, des fonctions de protéines associées à une maladie à l'intérieur de cellules peuvent être efficacement et spécifiquement brouillées, ce qui permet d'atteindre l'objectif de traitement de la maladie. De plus, le procédé diffère des stratégies classiques permettant d'exprimer des nanocorps dans des cellules à l'aide d'ADN ou de virus en tant que vecteurs. Le procédé supprime les risques associés à la modification de la séquence génomique de cellules hôtes, est sûr, permet un retrait facile, et est tout à fait approprié aux exigences de conception et de production des médicaments cliniques.
(ZH) mRNA编码的纳米抗体及其应用,特别是纳米抗体药物领域。为了解决以上问题,用RNA编码纳米抗体调控胞内蛋白的新思路和方法系统。mRNA编码的纳米抗体,该mRNA携带的编码信息在细胞内被识别、翻译、表达出可以与靶蛋白结合的单链纳米抗体。采用该方法可以高效、特异性地干预细胞内部疾病相关蛋白的功能,并以此实现治疗疾病的目的。同时该方法和以DNA或病毒为载体在细胞内表达纳米抗体的常用策略不同,该方法摒除了对宿主细胞基因组序列造成改变的风险,具有安全和容易清除的特点,非常适合临床药物设计生产的需要。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)